BGB-11417, POSACONAZOLE, Azacitidine betapharm 25 mg/mL powder for suspension for injection, BGB-11417, BGB-11417, AZACITIDINE
BGB-11417-103
Phase 2 small_molecule active
Quick answer
BGB-11417, POSACONAZOLE, Azacitidine betapharm 25 mg/mL powder for suspension for injection, BGB-11417, BGB-11417, AZACITIDINE for Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN. is a Phase 2 program (small_molecule) at Beone Medicines Ireland Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Beone Medicines Ireland Limited
- Indication
- Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active